shutterstock-51116584-web
Giordano Aita / Shutterstock.com
25 June 2014Americas

BIO 2014: Public access to medicine at risk in US - report

The American public's access to new and effective medicines could be at risk as a result of the US Supreme Court's decisions in the Prometheus and Myriad cases, and the resulting guidance for examiners from the US Patent and Trademark Office (USPTO), according to a report presented to the 2014 BIO International Convention in San Diego today (Wednesday).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 June 2014   Patent rejections based on 35 USC §101, which relate to patent eligibility, are “incredibly case-specific”, making it difficult to identify trends or draw broad conclusions, said Matthew McFarlane, a partner at Robins, Kaplan, Miller & Ciresi LLP at the BIO International Convention yesterday.

More on this story

Americas
26 June 2014   Patent rejections based on 35 USC §101, which relate to patent eligibility, are “incredibly case-specific”, making it difficult to identify trends or draw broad conclusions, said Matthew McFarlane, a partner at Robins, Kaplan, Miller & Ciresi LLP at the BIO International Convention yesterday.

More on this story

Americas
26 June 2014   Patent rejections based on 35 USC §101, which relate to patent eligibility, are “incredibly case-specific”, making it difficult to identify trends or draw broad conclusions, said Matthew McFarlane, a partner at Robins, Kaplan, Miller & Ciresi LLP at the BIO International Convention yesterday.